The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Development of a clinical trial immunohistochemistry (IHC) assay using a novel antibody to CD38.
 
Karen Wakamiya
Employment - Agilent
Stock and Other Ownership Interests - Agilent; Amgen
 
Marsha Hudson
Employment - Agilent
Stock and Other Ownership Interests - Agilent
 
Hayley Finkelstein
Employment - Agilent
Stock and Other Ownership Interests - Amgen
 
Mai Nguyen
Employment - Agilent
Stock and Other Ownership Interests - Agilent
Patents, Royalties, Other Intellectual Property - Dako/Agilent Technologies
 
Sara Alvarez
Employment - Agilent
Stock and Other Ownership Interests - Agilent
 
Brad Neill
Employment - Agilent
Stock and Other Ownership Interests - Baxter
 
Josette William
Consulting or Advisory Role - Agilent
 
Debra Ann Hanks
Employment - Premier Pathology Laboratories, Inc.
Leadership - Premier Pathology Laboratories, Inc.
Stock and Other Ownership Interests - Premier Pathology Laboratories, Inc.
Patents, Royalties, Other Intellectual Property - Agilent
 
Malinka Jansson
Employment - Agilent
Stock and Other Ownership Interests - Agilent
 
Adam Northrup
Employment - Agilent
Stock and Other Ownership Interests - Agilent
Travel, Accommodations, Expenses - Agilent
 
John David Alvarez
Employment - Janssen; Sanofi (I)
Stock and Other Ownership Interests - Janssen; Sanofi (I)
Travel, Accommodations, Expenses - Janssen; Sanofi (I)
 
Emin Oroudjev
Employment - Agilent
Leadership - Agilent
Stock and Other Ownership Interests - Agilent
Research Funding - Bristol-Myers Squibb; Janssen